{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:12:25Z","timestamp":1793056345779,"version":"4.5.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"DOI":"10.1007\/s42000-026-00804-0","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:14:29Z","timestamp":1784574869000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["EndoBridge 2025: pearls and highlights"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-7662","authenticated-orcid":false,"given":"Bulent Okan","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Armenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Carling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Ciudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketan","family":"Dhatariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Fountas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Fr\u00fchbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Grammatikopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica Lind\u00e9n","family":"Hirschberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Jawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Jonklaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Lezaic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"MacFarlane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Philis-Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Rose N.","family":"San Diego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heide","family":"Siggelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Stratakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"4","key":"804_CR1","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s42000-025-00708-5","volume":"24","author":"BO Yildiz","year":"2025","unstructured":"Yildiz BO, Armeni E, Balodimou C, Biondi B, Ciudin A, Fr\u00fchbeck G et al (2025) EndoBridge 2024: pearls and highlights. Horm (Athens) 24(4):923\u2013946. https:\/\/doi.org\/10.1007\/s42000-025-00708-5","journal-title":"Horm (Athens)"},{"key":"804_CR2","doi-asserted-by":"publisher","first-page":"e1652","DOI":"10.1210\/clinem\/dgae087","volume":"109","author":"AS Papazoglou","year":"2024","unstructured":"Papazoglou AS, Leite AR, Moysidis DV et al (2024) Serum prolactin levels and mortality in adults without prolactinoma: a meta-analysis. J Clin Endocrinol Metab 109:e1652\u2013e1664. https:\/\/doi.org\/10.1210\/clinem\/dgae087","journal-title":"J Clin Endocrinol Metab"},{"key":"804_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11102-025-01594-1","volume":"28","author":"I Ayalon-Dangur","year":"2025","unstructured":"Ayalon-Dangur I, Shimon I, Shochat T et al (2025) Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study. Pituitary 28:116. https:\/\/doi.org\/10.1007\/s11102-025-01594-1","journal-title":"Pituitary"},{"key":"804_CR4","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","volume":"19","author":"S Petersenn","year":"2023","unstructured":"Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement. Nat Rev Endocrinol 19:722\u2013740. https:\/\/doi.org\/10.1038\/s41574-023-00886-5","journal-title":"Nat Rev Endocrinol"},{"key":"804_CR5","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/S2213-8587(25)00227-X","volume":"13","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Varlamov EV, Akirov A et al (2025) Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 13:874\u2013890. https:\/\/doi.org\/10.1016\/S2213-8587(25)00227-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"804_CR6","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","volume":"17","author":"G Raverot","year":"2021","unstructured":"Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T (2021) Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 17:671\u2013684. https:\/\/doi.org\/10.1038\/s41574-021-00550-w","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"804_CR7","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"804_CR8","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1210\/jc.2010-0537","volume":"95","author":"A Raappana","year":"2010","unstructured":"Raappana A, Koivukangas J, Ebeling T, Piril\u00e4 T (2010) Incidence of pituitary adenomas in Northern Finland in 1992\u20132007. J Clin Endocrinol Metab 95(9):4268\u20134275. https:\/\/doi.org\/10.1210\/jc.2010-0537","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"804_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/ejendo\/lvad070","volume":"189","author":"R Hamblin","year":"2023","unstructured":"Hamblin R, Fountas A, Lithgow K et al (2023) Natural history of non-functioning pituitary microadenomas: results from the UK non- functioning pituitary adenoma consortium. Eur J Endocrinol 189(1):87\u201395. https:\/\/doi.org\/10.1093\/ejendo\/lvad070","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"804_CR10","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/ejendo\/lvaf091","volume":"192","author":"A Fountas","year":"2025","unstructured":"Fountas A, Lithgow K, Loughrey PB et al (2025) Conservatively managed non-functioning pituitary macroadenomas-cohort study from the UK Non-functioning Pituitary Adenoma Consortium. Eur J Endocrinol 192(5):680\u2013690. https:\/\/doi.org\/10.1093\/ejendo\/lvaf091","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"804_CR11","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41574-025-01134-8","volume":"21","author":"M Fleseriu","year":"2025","unstructured":"Fleseriu M, Gurnell M, McCormack A, The Pituitary Society International Incidentaloma Consensus Group (2025) Pituitary incidentaloma: a Pituitary Society international consensus guideline statement. Nat Rev Endocrinol 21(10):638\u2013655. https:\/\/doi.org\/10.1038\/s41574-025-01134-8","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"804_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.beem.2013.10.003","volume":"27","author":"O Koulouri","year":"2013","unstructured":"Koulouri O, Moran C, Halsall D, Chatterjee K, Gurnell M (2013) Pitfalls in the measurement and interpretation of thyroid function tests. Best Pract Res Clin Endocrinol Metab Dec 27(6):745\u2013762. https:\/\/doi.org\/10.1016\/j.beem.2013.10.003","journal-title":"Best Pract Res Clin Endocrinol Metab Dec"},{"issue":"4","key":"804_CR13","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1210\/clinem\/dgad681","volume":"15","author":"C Moran","year":"2024","unstructured":"Moran C, Schoenmakers N, Halsall D et al (2024) Approach to the Patient with Raised Thyroid Hormones and Nonsuppressed TSH. J Clin Endocrinol Metab Mar 15(4):1094\u20131108. https:\/\/doi.org\/10.1210\/clinem\/dgad681","journal-title":"J Clin Endocrinol Metab Mar"},{"issue":"4","key":"804_CR14","doi-asserted-by":"publisher","first-page":"e240125","DOI":"10.1530\/ETJ-24-0125","volume":"13","author":"L Persani","year":"2024","unstructured":"Persani L, Rodien P, Moran C et al (2024) European Thyroid Association Guidelines on diagnosis and management of genetic disorders of thyroid hormone transport, metabolism and action. Eur Thyroid J 13(4):e240125. https:\/\/doi.org\/10.1530\/ETJ-24-0125","journal-title":"Eur Thyroid J"},{"issue":"4","key":"804_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/17446651.2025.2492789","volume":"20","author":"J Jonklaas","year":"2025","unstructured":"Jonklaas J (2025) The effects of levothyroxine monotherapy versus combination therapy on quality of life and patient satisfaction. Expert Rev Endocrinol Metab 20(4):317\u2013325. https:\/\/doi.org\/10.1080\/17446651.2025.2492789","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"11","key":"804_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1089\/thy.2021.0270","volume":"31","author":"JM Millan-Alanis","year":"2021","unstructured":"Millan-Alanis JM, Gonz\u00e1lez-Gonz\u00e1lez JG, Flores-Rodr\u00edguez A et al (2021) Benefits and Harms of Levothyroxine\/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis. Thyroid 31(11):1613\u20131625. https:\/\/doi.org\/10.1089\/thy.2021.0270","journal-title":"Thyroid"},{"issue":"11","key":"804_CR17","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1210\/clinem\/dgaf449","volume":"110","author":"S Bahl","year":"2025","unstructured":"Bahl S, Taylor PN, Premawardhana LD et al (2025) Risk of Death and Adverse Effects in Patients on Liothyronine: A Multisource Systematic Review and Meta-analysis. J Clin Endocrinol Metab 110(11):3278\u20133288. https:\/\/doi.org\/10.1210\/clinem\/dgaf449","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"804_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1089\/thy.2020.0720","volume":"31","author":"J Jonklaas","year":"2021","unstructured":"Jonklaas J, Bianco AC, Cappola AR et al (2021) Evidence-Based Use of Levothyroxine\/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document. Thyroid 31(2):156\u2013182. https:\/\/doi.org\/10.1089\/thy.2020.0720","journal-title":"Thyroid"},{"issue":"3","key":"804_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1210\/clinem\/dgae651","volume":"18","author":"FE de Lima Beltr\u00e3o","year":"2025","unstructured":"de Lima Beltr\u00e3o FE, Carvalhal G, de Almeida Beltr\u00e3o DC et al (2025) Treatment Preferences in Patients with Hypothyroidism. J Clin Endocrinol Metab Feb 18(3):887\u2013900. https:\/\/doi.org\/10.1210\/clinem\/dgae651","journal-title":"J Clin Endocrinol Metab Feb"},{"issue":"1","key":"804_CR20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3803\/EnM.2020.833","volume":"36","author":"CC Yang","year":"2021","unstructured":"Yang CC, Hsu Y, Liou JY (2021) Efficacy of Ethanol Ablation for Benign Thyroid Cysts and Predominantly Cystic Nodules: A Systematic Review and Meta-Analysis. Endocrinol Metab (Seoul) Feb 36(1):81\u201395. https:\/\/doi.org\/10.3803\/EnM.2020.833","journal-title":"Endocrinol Metab (Seoul) Feb"},{"issue":"10","key":"804_CR21","doi-asserted-by":"publisher","first-page":"6089","DOI":"10.1007\/s00330-025-11543-y","volume":"35","author":"X Zhao","year":"2025","unstructured":"Zhao X, Xue J, Yu W et al (2025) The long-term effects of thermal ablation for benign thyroid nodules: a systematic review and meta-analysis. Eur Radiol Oct 35(10):6089\u20136100. https:\/\/doi.org\/10.1007\/s00330-025-11543-y","journal-title":"Eur Radiol Oct"},{"key":"804_CR22","doi-asserted-by":"publisher","first-page":"110706","DOI":"10.1016\/j.radonc.2025.110706","volume":"205","author":"E Toraih","year":"2025","unstructured":"Toraih E, Hussein M, Elshazli R et al (2025) Therapeutic outcomes and safety of radiofrequency ablation for primary papillary thyroid carcinoma: A game-changing meta-analysis. Radiother Oncol Apr 205:110706. https:\/\/doi.org\/10.1016\/j.radonc.2025.110706","journal-title":"Radiother Oncol Apr"},{"issue":"25","key":"804_CR23","doi-asserted-by":"publisher","first-page":"S1530","DOI":"10.1016\/j.eprac.2025.07.024","volume":"6","author":"HI Coerts","year":"2025","unstructured":"Coerts HI, D\u2019Mello B, Verburg FA et al (2025) Thyroid Arterial Embolization for the Management of Benign and Malignant Thyroid Disease: A Systematic Review. Endocr Pract Aug 6(25):S1530\u2013891X. https:\/\/doi.org\/10.1016\/j.eprac.2025.07.024","journal-title":"Endocr Pract Aug"},{"key":"804_CR24","first-page":"e220189","volume":"8","author":"HB Burch","year":"2022","unstructured":"Burch HB, Perros P, Bednarczuk T, Cooper DS, Dolman PJ, Leung AM, Mombaerts I, Salvi M, Stan MN (2022) Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association. Eur Thyroid J 8:e220189","journal-title":"Eur Thyroid J"},{"key":"804_CR25","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trial-snapshot-tepezza"},{"issue":"1","key":"804_CR26","doi-asserted-by":"publisher","first-page":"ETJ250363","DOI":"10.1530\/ETJ-25-0363","volume":"15","author":"M Salvi","year":"2026","unstructured":"Salvi M (2026) What has changed in Thyroid Eye Disease in the last five years (2020\u20132025). Eur Thyroid J 15(1):ETJ250363. https:\/\/doi.org\/10.1530\/ETJ-25-0363","journal-title":"Eur Thyroid J"},{"key":"804_CR27","doi-asserted-by":"crossref","unstructured":"Biscarini F, Masetti G, Muller I et al (2024) Gut Microbiome Associated With Graves\u2019 Disease and Graves Orbitopathy: The INDIGO Multicenter European Study. J Clin Endocrinol Metab 108:2065\u20132077. Erratum in: J Clin Endocrinol Metab. 2024 109 e880","DOI":"10.1210\/clinem\/dgad596"},{"issue":"6","key":"804_CR28","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/thy.2023.0621","volume":"34","author":"K Shin","year":"2024","unstructured":"Shin K, Choung H, Lee MJ et al (2024) A Preliminary Evaluation of the Diagnostic Performance of a Smartphone-Based Machine Learning-Assisted System for Evaluation of Clinical Activity Score in Digital Images of Thyroid-Associated Orbitopathy. Thyroid Jun 34(6):744\u2013752. https:\/\/doi.org\/10.1089\/thy.2023.0621","journal-title":"Thyroid Jun"},{"issue":"7","key":"804_CR29","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.mayocp.2024.01.011","volume":"99","author":"AA Khan","year":"2024","unstructured":"Khan AA, Slart RHJA, Ali DS et al (2024) Osteoporotic Fractures: Diagnosis, Evaluation, and Significance From the International Working Group on DXA Best Practices. Mayo Clin Proc 99(7):1127\u20131141. https:\/\/doi.org\/10.1016\/j.mayocp.2024.01.011","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"804_CR30","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16(1):82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"issue":"3","key":"804_CR31","doi-asserted-by":"publisher","first-page":"101775","DOI":"10.1016\/j.berh.2022.101775","volume":"36","author":"JJ Carey","year":"2022","unstructured":"Carey JJ, Chih-Hsing Wu P, Bergin D (2022) Risk assessment tools for osteoporosis and fractures in 2022. Best Pract Res Clin Rheumatol 36(3):101775. https:\/\/doi.org\/10.1016\/j.berh.2022.101775","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"17","key":"804_CR32","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1056\/NEJMp2000589","volume":"382","author":"MJ Pencina","year":"2020","unstructured":"Pencina MJ, Goldstein BA, D\u2019Agostino RB (2020) Prediction Models \u2013 Development, Evaluation, and Clinical Application. N Engl J Med 382(17):1583\u20131586. https:\/\/doi.org\/10.1056\/NEJMp2000589","journal-title":"N Engl J Med"},{"issue":"8","key":"804_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jbmr.1956","volume":"28","author":"KH Rubin","year":"2013","unstructured":"Rubin KH, Friis-Holmberg T, Hermann AP, Abrahamsen B, Brixen K (2013) Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Min Res 28(8):1701\u20131717. https:\/\/doi.org\/10.1002\/jbmr.1956","journal-title":"J Bone Min Res"},{"issue":"25","key":"804_CR34","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1056\/NEJMp068249","volume":"355","author":"JH Ware","year":"2006","unstructured":"Ware JH (2006) The limitations of risk factors as prognostic tools. N Engl J Med 355(25):2615\u20132617. https:\/\/doi.org\/10.1056\/NEJMp068249","journal-title":"N Engl J Med"},{"issue":"5","key":"804_CR35","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","volume":"14","author":"DM Black","year":"1999","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Min Res 14(5):821\u2013828. https:\/\/doi.org\/10.1359\/jbmr.1999.14.5.821","journal-title":"J Bone Min Res"},{"issue":"8","key":"804_CR36","doi-asserted-by":"publisher","first-page":"e2329253","DOI":"10.1001\/jamanetworkopen.2023.29253","volume":"6","author":"C Ye","year":"2023","unstructured":"Ye C, Leslie WD, Morin SN et al (2023) Adjusting FRAX Estimates of Fracture Probability Based on a Positive Vertebral Fracture Assessment. JAMA Netw Open 6(8):e2329253. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29253","journal-title":"JAMA Netw Open"},{"issue":"8","key":"804_CR37","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1210\/clinem\/dgaf170","volume":"15","author":"AA Khan","year":"2025","unstructured":"Khan AA, Ali DS, Appelman-Dijkstra NM et al (2025) X-Linked Hypophosphatemia Management in Adults: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab Jul 15(8):2353\u20132370. https:\/\/doi.org\/10.1210\/clinem\/dgaf170","journal-title":"J Clin Endocrinol Metab Jul"},{"issue":"7","key":"804_CR38","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1210\/clinem\/dgaf093","volume":"17","author":"DS Ali","year":"2025","unstructured":"Ali DS, Carpenter TO, Imel EA et al (2025) X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline. J Clin Endocrinol Metab Jun 17(7):2055\u20132070. https:\/\/doi.org\/10.1210\/clinem\/dgaf093","journal-title":"J Clin Endocrinol Metab Jun"},{"issue":"6","key":"804_CR39","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1210\/clinem\/dgae890","volume":"19","author":"DS Ali","year":"2025","unstructured":"Ali DS, Mirza RD, Alsarraf F et al (2025) Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Adult Patients With X-Linked Hypophosphatemia. J Clin Endocrinol Metab May 19(6):1767\u20131780. https:\/\/doi.org\/10.1210\/clinem\/dgae890","journal-title":"J Clin Endocrinol Metab May"},{"issue":"5","key":"804_CR40","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1210\/clinem\/dgaf011","volume":"22","author":"DS Ali","year":"2025","unstructured":"Ali DS, Mirza RD, Hussein S et al (2025) Systematic Review: Efficacy of Medical Therapy on Outcomes Important to Pediatric Patients With X-Linked Hypophosphatemia. J Clin Endocrinol Metab Apr 22(5):1205\u20131217. https:\/\/doi.org\/10.1210\/clinem\/dgaf011","journal-title":"J Clin Endocrinol Metab Apr"},{"issue":"8","key":"804_CR41","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S2213-8587(25)00119-6","volume":"13","author":"ML Brandi","year":"2025","unstructured":"Brandi ML, Pieterman CRC, English KA et al (2025) Multiple Endocrine Neoplasia Type 1 (MEN1): Recommendations and Guidelines for Best Practice. Lancet Diabetes Endocrinol 13(8):699\u2013721. https:\/\/doi.org\/10.1016\/S2213-8587(25)00119-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"804_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4158\/EP10379.RA","volume":"17","author":"PJ Newey","year":"2011","unstructured":"Newey PJ, Thakker RV (2011) Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. Endocr Pract 17:8\u201317. https:\/\/doi.org\/10.4158\/EP10379.RA","journal-title":"Endocr Pract"},{"key":"804_CR43","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00268-022-06863-9","volume":"47","author":"S Rajan","year":"2023","unstructured":"Rajan S, Gracie D, Aspinall S (2023) Does surgeon volume impact morbidity following parathyroidectomy? A study of 16,140 parathyroidectomies from the UK Registry of Endocrine and Thyroid Surgery (UKRETS) Database. World J Surg 47:1221\u20131230. https:\/\/doi.org\/10.1007\/s00268-022-06863-9","journal-title":"World J Surg"},{"key":"804_CR44","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1007\/s00268-016-3624-9","volume":"40","author":"WP Kluijfhout","year":"2016","unstructured":"Kluijfhout WP, Beninato T, Drake FT et al (2016) Unilateral clearance for primary hyperparathyroidism in selected patients with multiple endocrine neoplasia type 1. World J Surg 40:2964\u20132969. https:\/\/doi.org\/10.1007\/s00268-016-3624-9","journal-title":"World J Surg"},{"key":"804_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","volume":"52","author":"F Giusti","year":"2016","unstructured":"Giusti F, Cianferotti L, Gronchi G et al (2016) Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia type 1 (MEN1). Endocrine 52:495\u2013506. https:\/\/doi.org\/10.1007\/s12020-015-0696-5","journal-title":"Endocrine"},{"key":"804_CR46","doi-asserted-by":"publisher","first-page":"17055","DOI":"10.1038\/nrdp.2017.55","volume":"3","author":"M Mannstadt","year":"2017","unstructured":"Mannstadt M, Bilezikian JP, Thakker RV et al (2017) Hypoparathyroidism. Nat Rev Dis Primers 3:17055. https:\/\/doi.org\/10.1038\/nrdp.2017.55","journal-title":"Nat Rev Dis Primers"},{"key":"804_CR47","doi-asserted-by":"publisher","first-page":"156335","DOI":"10.1016\/j.metabol.2025.156335","volume":"171","author":"AA Khan","year":"2025","unstructured":"Khan AA, Ali DS, Bilezikian JP et al (2025) Best practice recommendations for the diagnosis and management of hypoparathyroidism. Metabolism 171:156335. https:\/\/doi.org\/10.1016\/j.metabol.2025.156335","journal-title":"Metabolism"},{"key":"804_CR48","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1002\/jbmr.4673","volume":"37","author":"L Yao","year":"2022","unstructured":"Yao L, Chen J, Li M, Wang Y, Wu Y, Lin X et al (2022) Complications and symptoms of chronic hypoparathyroidism: a systematic review and meta-analysis. J Bone Min Res 37:2642\u20132653. https:\/\/doi.org\/10.1002\/jbmr.4673","journal-title":"J Bone Min Res"},{"key":"804_CR49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cen.14128","volume":"92","author":"H Siggelkow","year":"2020","unstructured":"Siggelkow H, Clarke BL, Germak J, Marelli C, Chen K, Dahl NV (2020) Burden of illness in patients with chronic hypoparathyroidism not adequately controlled on conventional therapy. Clin Endocrinol (Oxf) 92:159\u2013168. https:\/\/doi.org\/10.1111\/cen.14128","journal-title":"Clin Endocrinol (Oxf)"},{"key":"804_CR50","doi-asserted-by":"publisher","first-page":"dgae693","DOI":"10.1210\/clinem\/dgae693","volume":"109","author":"BL Clarke","year":"2024","unstructured":"Clarke BL, Khan AA, Rejnmark L et al (2024) Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the Phase 3 PaTHway trial. J Clin Endocrinol Metab 109:dgae693. https:\/\/doi.org\/10.1210\/clinem\/dgae693","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"804_CR51","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","volume":"67","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez GE, Davis GM, ElSayed NA et al (2024) Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia Aug 67(8):1455\u20131479. https:\/\/doi.org\/10.1007\/s00125-024-06183-8","journal-title":"Diabetologia Aug"},{"issue":"7","key":"804_CR52","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.2337\/dc09-9032","volume":"32","author":"AE Kitabchi","year":"2009","unstructured":"Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN (2009) Hyperglycemic crises in adult patients with diabetes. Diabetes Care Jul 32(7):1335\u20131343. https:\/\/doi.org\/10.2337\/dc09-9032","journal-title":"Diabetes Care Jul"},{"issue":"6","key":"804_CR53","doi-asserted-by":"publisher","first-page":"e14788","DOI":"10.1111\/dme.14788","volume":"39","author":"K Dhatariya","year":"2022","unstructured":"Dhatariya K, on Behalf of the Joint British Diabetes Societies for Inpatient Care (2022) The management of diabetic ketoacidosis in adults \u2013 an updated guideline from the Joint British Diabetes Society for Inpatient Care. Diabet Med Jun 39(6):e14788. https:\/\/doi.org\/10.1111\/dme.14788","journal-title":"Diabet Med Jun"},{"issue":"4","key":"804_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1900\/RDS.2016.13.217","volume":"13","author":"K Dhatariya","year":"2016","unstructured":"Dhatariya K (2016) Blood ketones - measurement, interpretation, limitations and utility in the management of diabetic ketoacidosis. Rev Diabet Stud 2016 Winter 13(4):217\u2013225. https:\/\/doi.org\/10.1900\/RDS.2016.13.217","journal-title":"Rev Diabet Stud 2016 Winter"},{"issue":"3","key":"804_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-8587(20)30381-8","volume":"9","author":"FJ Pasquel","year":"2021","unstructured":"Pasquel FJ, Lansang MC, Dhatariya K, Umpierrez GE (2021) Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol 9(3):174\u2013188. https:\/\/doi.org\/10.1016\/S2213-8587(20)30381-8","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"804_CR56","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.2337\/dc22-0716","volume":"45","author":"EK Spanakis","year":"2022","unstructured":"Spanakis EK, Urrutia A, Galindo RJ et al (2022) Continuous glucose monitoring-guided insulin administration in hospitalized patients with diabetes: a randomized clinical trial. Diabetes Care 45(10):2369\u20132375. https:\/\/doi.org\/10.2337\/dc22-0716","journal-title":"Diabetes Care"},{"issue":"1","key":"804_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5863\/1551-6776-30.1.123","volume":"30","author":"AB Hamilton","year":"2025","unstructured":"Hamilton AB, Rajagopal N, Ngo C, Hendrix-Dicken AD, Mercer S, Condren M (2025) Survey of Diabetes Technology in the Pediatric Inpatient Setting. J Pediatr Pharmacol Ther 30(1):123\u2013128. https:\/\/doi.org\/10.5863\/1551-6776-30.1.123","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"804_CR58","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1089\/dia.2024.0343","volume":"27","author":"MS Hughes","year":"2025","unstructured":"Hughes MS, Pasquel FJ, Davis GM, Lal RA, Buckingham BA, Boughton CK, Brown SA, Bally L (2025) Toward Automation: The Road Traveled and Road Ahead for Integrating Automated Insulin Delivery into Inpatient Care. Diabetes Technol Ther 27(3):217\u2013242. https:\/\/doi.org\/10.1089\/dia.2024.0343","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"804_CR59","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1177\/1932296820955243","volume":"15","author":"KM Lichtenegger","year":"2021","unstructured":"Lichtenegger KM, Aberer F, Tuca AC et al (2021) Safe and Sufficient Glycemic Control by Using a Digital Clinical Decision Support System for Patients With Type 2 Diabetes in a Routine Setting on General Hospital Wards. J Diabetes Sci Technol 15(2):231\u2013235. https:\/\/doi.org\/10.1177\/1932296820955243","journal-title":"J Diabetes Sci Technol"},{"key":"804_CR60","doi-asserted-by":"publisher","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2024) Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet Nov 23;404(10467):2077\u20132093. 10.1016\/S0140-6736(24)02317-1. Epub 2024 Nov 13. Erratum in: Lancet (2025) 405(10485):1146. https:\/\/doi.org\/10.1016\/S0140-6736(25)00620-8","DOI":"10.1016\/S0140-6736(25)00620-8"},{"key":"804_CR61","doi-asserted-by":"publisher","unstructured":"Luk A, Wild SH, Jones S, Anjana RM, Hivert MF, McCaffrey J, Gregg EW, Misra S (2025) Early-onset type 2 diabetes: the next major diabetes transition. Lancet. Jun 28;405(10497):2313\u20132326. 10.1016\/S0140-6736(25)00830-X. Epub 2025 Jun 23. Erratum in: Lancet. 2025;406(10512):1564. https:\/\/doi.org\/10.1016\/S0140-6736(25)02057-4","DOI":"10.1016\/S0140-6736(25)02057-4"},{"issue":"1","key":"804_CR62","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dci20-0053","volume":"44","author":"F Hill-Briggs","year":"2021","unstructured":"Hill-Briggs F, Adler NE, Berkowitz SA et al (2021) Social Determinants of Health and Diabetes: A Scientific Review. Diabetes Care 44(1):258\u2013279. https:\/\/doi.org\/10.2337\/dci20-0053","journal-title":"Diabetes Care"},{"issue":"7","key":"804_CR63","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11892-024-01541-7","volume":"24","author":"P Mensah","year":"2024","unstructured":"Mensah P, Valdez K, Gyawali A, Snell-Bergeon J (2024) Social and Structural Determinants of Cardiovascular Complications of Diabetes. Curr Diab Rep 24(7):147\u2013157. https:\/\/doi.org\/10.1007\/s11892-024-01541-7","journal-title":"Curr Diab Rep"},{"issue":"Supplement 1","key":"804_CR64","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"A American Diabetes Association Profe","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes A (2026) Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes 2026. Diabetes Care 49(Supplement 1):S183\u2013S215. https:\/\/doi.org\/10.2337\/dc26-S009","journal-title":"Diabetes Care"},{"key":"804_CR65","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","volume":"59","author":"P G\u00e6de","year":"2016","unstructured":"G\u00e6de P, Oellgaard J, Carstensen B et al (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59:2298\u20132307. https:\/\/doi.org\/10.1007\/s00125-016-4065-6","journal-title":"Diabetologia"},{"key":"804_CR66","unstructured":"World Obesity Federation (2025) Global Obesity Observatory 2025 accessed September : https:\/\/data.worldobesity.org"},{"issue":"9","key":"804_CR67","doi-asserted-by":"publisher","first-page":"bqaf121","DOI":"10.1210\/endocr\/bqaf121","volume":"166","author":"RE Ruggiero-Ruff","year":"2025","unstructured":"Ruggiero-Ruff RE, Coss D (2025) Neuroendocrinology and the Genetics of Obesity. Endocrinology 166(9):bqaf121. https:\/\/doi.org\/10.1210\/endocr\/bqaf121","journal-title":"Endocrinology"},{"issue":"8","key":"804_CR68","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/nu14081597","volume":"14","author":"V Catal\u00e1n","year":"2022","unstructured":"Catal\u00e1n V, Avil\u00e9s-Olmos I, Rodr\u00edguez A et al (2022) Time to Consider the Exposome Hypothesis in the Development of the Obesity Pandemic. Nutrients 14(8):1597. https:\/\/doi.org\/10.3390\/nu14081597","journal-title":"Nutrients"},{"issue":"11","key":"804_CR69","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1096\/fj.00-0829hyp","volume":"15","author":"G Fr\u00fchbeck","year":"2001","unstructured":"Fr\u00fchbeck G, G\u00f3mez-Ambrosi J (2001) Rationale for the existence of additional adipostatic hormones. FASEB 15(11):1996\u20132006. https:\/\/doi.org\/10.1096\/fj.00-0829hyp","journal-title":"FASEB"},{"issue":"2","key":"804_CR70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00125-003-1053-4","volume":"46","author":"G Fr\u00fchbeck","year":"2003","unstructured":"Fr\u00fchbeck G, G\u00f3mez-Ambrosi J (2003) Control of body weight: a physiologic and transgenic perspective. Diabetologia 46(2):143\u2013172. https:\/\/doi.org\/10.1007\/s00125-003-1053-4","journal-title":"Diabetologia"},{"issue":"2","key":"804_CR71","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000497124","volume":"12","author":"L Gema Fr\u00fchbeck","year":"2019","unstructured":"Gema Fr\u00fchbeck L, Busetto D, Dicker V, Yumuk et al (2019) The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts 12(2):131\u2013136. https:\/\/doi.org\/10.1159\/000497124","journal-title":"Obes Facts"},{"issue":"9","key":"804_CR72","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","volume":"30","author":"L Busetto","year":"2024","unstructured":"Busetto L, Dicker D, Fr\u00fchbeck G, Jason CG, Halford P, Sbraccia V, Yumuk, Gijs H, Goossens (2024) A new framework for the diagnosis, staging and management of obesity in adults. Nat Med 30(9):2395\u20132399. https:\/\/doi.org\/10.1038\/s41591-024-03095-3","journal-title":"Nat Med"},{"issue":"1","key":"804_CR73","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41392-024-01841-0","volume":"9","author":"D Walzik","year":"2024","unstructured":"Walzik D, Tiffany YW, Chirino P, Zimmer, Niklas Joisten (2024) Molecular insights of exercise therapy in disease prevention and treatment. Signal Transduct Target Ther 9(1):138. https:\/\/doi.org\/10.1038\/s41392-024-01841-0","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"804_CR74","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s42255-020-0251-4","volume":"2","author":"LL Mark Hargreaves","year":"2020","unstructured":"Mark Hargreaves LL, Spriet (2020) Skeletal muscle energy metabolism during exercise. Nat Metab 2(9):817\u2013828. https:\/\/doi.org\/10.1038\/s42255-020-0251-4","journal-title":"Nat Metab"},{"issue":"3","key":"804_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrendo.2016.162","volume":"13","author":"M Lykke Sylow","year":"2017","unstructured":"Lykke Sylow M, Kleinert EA, Richter, Thomas E, Jensen (2017) Exercise-stimulated glucose uptake - regulation and implications for glycaemic control. Nat Rev Endocrinol 13(3):133\u2013148. https:\/\/doi.org\/10.1038\/nrendo.2016.162","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"804_CR76","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"issue":"3","key":"804_CR77","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3):205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"issue":"9","key":"804_CR78","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-8587(24)00182-7","volume":"12","author":"BM McGowan","year":"2024","unstructured":"McGowan BM, Bruun JM, Capehorn M et al (2024) Efficacy and safety of once-weekly semaglutide 2\u00b74\u00a0mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial. Lancet Diabetes Endocrinol 12(9):631\u2013642. https:\/\/doi.org\/10.1016\/S2213-8587(24)00182-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"804_CR79","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A et al (2025) Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med 392(10):958\u2013971. https:\/\/doi.org\/10.1056\/NEJMoa2410819","journal-title":"N Engl J Med"},{"issue":"10","key":"804_CR80","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","volume":"31","author":"B McGowan","year":"2025","unstructured":"McGowan B, Ciudin A, Baker JL et al (2025) A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults. Nat Med 31(10):3317\u20133329. https:\/\/doi.org\/10.1038\/s41591-025-03978-z","journal-title":"Nat Med"},{"issue":"42","key":"804_CR81","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van Roeters JE et al (2025) 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 46(42):4359\u20134378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"issue":"20","key":"804_CR82","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1001\/jama.2022.19294","volume":"328","author":"JA Halpern","year":"2024","unstructured":"Halpern JA, Davis AM, Brannigan RE (2024) Diagnosis and Treatment of Infertility in Men. JAMA 328(20):2056\u20132057. https:\/\/doi.org\/10.1001\/jama.2022.19294","journal-title":"JAMA"},{"issue":"6","key":"804_CR83","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/JU.0000000000004180","volume":"212","author":"RE Brannigan","year":"2024","unstructured":"Brannigan RE, Hermanson L, Kaczmarek J, Kim SK, Kirkby E, Tanrikut C (2024) Updates to Male Infertility: AUA\/ASRM Guideline. J Urol 212(6):789\u2013799. https:\/\/doi.org\/10.1097\/JU.0000000000004180","journal-title":"J Urol"},{"key":"804_CR84","unstructured":"World Health Organization (2021) WHO laboratory manual for the examination and processing of human semen, 6th edition. Geneva: WHO ISBN 978-92-4-003078-7"},{"key":"804_CR85","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00439-020-02202-x","volume":"140","author":"C Krausz","year":"2021","unstructured":"Krausz C, Riera-Escamilla A (2021) Disease gene discovery in male infertility: past, present and future. Hum Genet 140:7\u201319. https:\/\/doi.org\/10.1007\/s00439-020-02202-x","journal-title":"Hum Genet"},{"issue":"4","key":"804_CR86","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/andr.12502","volume":"6","author":"GM Colpi","year":"2018","unstructured":"Colpi GM, Francavilla S, Haidl G, Link K, Behre HM, Goulis DG, Krausz C, Giwercman A (2018) European Academy of Andrology guideline Management of oligo-astheno-teratozoospermia. Andrology 6(4):513\u2013524. https:\/\/doi.org\/10.1111\/andr.12502","journal-title":"Andrology"},{"issue":"5","key":"804_CR87","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1210\/jc.2017-00131","volume":"102","author":"CM Gordon","year":"2017","unstructured":"Gordon CM, Ackerman KE, Berga SL et al (2017) Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102(5):1413\u20131439. https:\/\/doi.org\/10.1210\/jc.2017-00131","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"804_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"804_CR89","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/humrep\/dead156","volume":"38","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A et al (2023) International PCOS Network. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod 38(9):1655\u20131679. https:\/\/doi.org\/10.1093\/humrep\/dead156","journal-title":"Hum Reprod"},{"issue":"4","key":"804_CR90","doi-asserted-by":"publisher","first-page":"hoae065","DOI":"10.1093\/hropen\/hoae065","volume":"2024","author":"N Panay","year":"2024","unstructured":"ESHRE ASRM, CREWHIRL and IMS Guideline Group on POI, Panay N, Anderson RA, Bennie A, Cedars M, Davies M, Ee C et al (2024) Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open 2024(4):hoae065. https:\/\/doi.org\/10.1093\/hropen\/hoae065","journal-title":"Hum Reprod Open"},{"issue":"4","key":"804_CR91","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/TEAM.9781879225855.ch3","volume":"2","author":"P Xekouki","year":"2011","unstructured":"Xekouki P, CA Stratakis (2011) Pheochromocytoma. Transl Endocrinol Metab 2(4):77\u2013127","journal-title":"Transl Endocrinol Metab"},{"key":"804_CR92","doi-asserted-by":"publisher","unstructured":"Jha A, de Luna K, Balili CA et al (2019) Clinical, diagnostic, and treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma. Front Oncol 9:53. eCollection 2019 https:\/\/doi.org\/10.3389\/fonc.2019.00053","DOI":"10.3389\/fonc.2019.00053"},{"key":"804_CR93","doi-asserted-by":"publisher","first-page":"680609","DOI":"10.3389\/fendo.2021.680609","volume":"12","author":"G Pitsava","year":"2021","unstructured":"Pitsava G, Settas N, Faucz FR, CA Stratakis (2021) Carney Triad, Carney-Stratakis Syndrome, 3PAS and Other Tumors Due to SDH Deficiency. Front Endocrinol (Lausanne) 12:680609. https:\/\/doi.org\/10.3389\/fendo.2021.680609","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"804_CR94","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00259-017-3896-9","volume":"45","author":"A Jha","year":"2018","unstructured":"Jha A, Ling A, Millo C, Gupta G et al (2018) Superiority of (68)Ga-DOTATATE over (18)FFDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. Eur J Nucl Med Mol Imaging 45(5):787\u2013797. https:\/\/doi.org\/10.1007\/s00259-017-3896-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"804_CR95","doi-asserted-by":"publisher","first-page":"1433582","DOI":"10.3389\/fendo.2024.1433582","volume":"13","author":"TJS Saavedra","year":"2024","unstructured":"Saavedra TJS, Nati-Castillo HA, Valderrama Cometa LA et al (2024) Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment. Front Endocrinol (Lausanne) Dec 13:15:1433582. https:\/\/doi.org\/10.3389\/fendo.2024.1433582","journal-title":"Front Endocrinol (Lausanne) Dec"},{"issue":"2","key":"804_CR96","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W et al (2016) Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 101(2):364\u2013389. https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"804_CR97","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2967\/jnumed.119.229914","volume":"61","author":"A Cuderman","year":"2020","unstructured":"Cuderman A, Senica K, Rep S, Hocevar M, Kocjan T, Sever MJ, Zaletel K, Lezaic L (2020) 18F-Fluorocholine PET\/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands. J Nucl Med 61(4):577\u2013583. https:\/\/doi.org\/10.2967\/jnumed.119.229914","journal-title":"J Nucl Med"},{"issue":"6","key":"804_CR98","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2967\/jnumed.115.165803","volume":"57","author":"SA Deppen","year":"2016","unstructured":"Deppen SA, Blume J, Bobbey AJ et al (2016) 68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. J Nucl Med 57(6):872\u2013878. https:\/\/doi.org\/10.2967\/jnumed.115.165803","journal-title":"J Nucl Med"},{"issue":"10","key":"804_CR99","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","volume":"46","author":"D Ta\u00efeb","year":"2019","unstructured":"Ta\u00efeb D, Hicks RJ, Hindi\u00e9 E et al (2019) European Association of Nuclear Medicine Practice Guideline\/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 46(10):2112\u20132137. https:\/\/doi.org\/10.1007\/s00259-019-04398-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"804_CR100","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, NETTER-1 investigators et al (2021) (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 22(12):1752\u20131763. https:\/\/doi.org\/10.1016\/S1470-2045(21)00572-6","journal-title":"Lancet Oncol"},{"issue":"4","key":"804_CR101","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1053\/j.semnuclmed.2024.02.002","volume":"54","author":"G Santo","year":"2024","unstructured":"Santo G, Di Santo G, Virgolini I (2024) Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives. Semin Nucl Med 54(4):557\u2013569. https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.02.002","journal-title":"Semin Nucl Med"},{"issue":"5","key":"804_CR102","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1210\/clinem\/dgac673","volume":"108","author":"AL Hirschberg","year":"2023","unstructured":"Hirschberg AL (2023) Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman. J Clin Endocrinol Metab 108(5):1243\u20131253. https:\/\/doi.org\/10.1210\/clinem\/dgac673","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"804_CR103","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1210\/jc.2003-031122","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz R, Sanchez LA, Knochenhauer ES et al (2004) Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89(2):453\u2013462. https:\/\/doi.org\/10.1210\/jc.2003-031122","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"804_CR104","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/gme.0b013e318185e249","volume":"16","author":"JI Torr\u00e9ns","year":"2009","unstructured":"Torr\u00e9ns JI, Sutton-Tyrrell K, Zhao X et al (2009) Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of women\u2019s health across the nation. Menopause 16(2):257\u2013264. https:\/\/doi.org\/10.1097\/gme.0b013e318185e249","journal-title":"Menopause"},{"issue":"3","key":"804_CR105","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1210\/jc.2010-0130","volume":"96","author":"M Markopoulos","year":"2011","unstructured":"Markopoulos M, Rizos D, Valsamakis G et al (2011) Hyperandrogenism in women with polycystic ovary syndrome persists after menopause. J Clin Endocrinol Metab 96(3):623\u2013631. https:\/\/doi.org\/10.1210\/jc.2010-0130","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"804_CR106","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/EJE-17-0111","volume":"177","author":"VRV Yance","year":"2017","unstructured":"Yance VRV, Marcondes JAM, Rocha MP et al (2017) Discriminating between virilizing ovary tumors and ovary hyperthecosis in postmenopausal women: clinical data, hormonal profiles and image studies. Eur J Endocrinol 177(1):93\u2013102. https:\/\/doi.org\/10.1530\/EJE-17-0111","journal-title":"Eur J Endocrinol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00804-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-026-00804-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-026-00804-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:14:31Z","timestamp":1784574871000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-026-00804-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":106,"alternative-id":["804"],"URL":"https:\/\/doi.org\/10.1007\/s42000-026-00804-0","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"26 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.O.Y., O.C., DY, G.H, A.L.H, C.S, D.G. J.J, L.L, M.G, M.L.B, M.G, N.K, A.F, S.J, and U.K have no relevant disclosures to report. A.K: Alexion, Amgen - Speaker, advisory board \/ Ascendis - Speaker, advisory board, research funding \/ Takeda - Advisory board, research funding \/ Amolyt - Research funding \/ All relevant financial relationships have been mitigated. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. A.C Honoraria from NovoNordisk, Eli Lilly, Astra Zeneca, Sanofi Aventis, ESTEVE, ZAMBON, Boehringher Ingelheim. Advisory Board: Eli Lilly, NovoNordisk, Boehringher Ingelheim. Data monitoring committee Boehringher Ingelheim. A T-P: Dexcom, Eli Lilly, Medtronic, Merck, National Institutes of Health, Novo\u00a0Nordisk. Speaking activities\/honoraria (paid to institution): Dexcom, Eli Lilly, Medtronic, Merck, Novo Nordisk Patents\/stocks: None. All funding is directed to employer, Scripps Health, with no transfer to the\u00a0speaker. B McG: Advisory work NovoNordisk, Astra Zeneca, J&J Ethicon, Lilly, Pfizer Educational work: Lilly, NovoNordisk, BI, Janssen, MSD, Sanofi, Astra Zeneca Institutional Research grant support: NovoNordisk Shareholder Reset Health and board member. D.P: Advisory work, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Educational Work, Eli Lilly, NovoNordisk, Research support - Stock holdings, Reset Health Ltd. G.F: Co-Director of Obesity Area, Cl\u00ednica Universidad de Navarra, Pamplona, Spain \/ Head of Metabolic Research Laboratory, Cl\u00ednica Univ. Navarra, Pamplona, Sp. \/ Full Professor & Vice Dean for Research, School of Medicine, Univ. Navarra \/ Participation in Advisory Boards: Lilly, Novo Nordisk, Regeneron, AstraZeneca, Boehringer Ingelheim & Marabou Foundation. H.S: Advisory boards: MSD, Lilly, Amgen, Servier, Takeda, UCB, Kyowa Kirin, Ipsen, Ascendis \/ Speaker engagements: MSD, Lilly, GSK, Servier, Amgen, Takeda, Merck\/Serono, UCB, Kyowa Kirin, Alexion, Biomarin, Bridge Bio, Ascendis \/ Research grant: Takeda; Ascendis. J.C Former President, Faculty for all densitometry courses, member position development conference committees 2015, 2019 and 2023, International Society for Clinical Densitometry. Paid Consultant, Speaker Fees, Travel Support, Small Research Grants in the past 20 years: Pfizer Canada, Pfizer Brazil, Hospira U.K. and Canada, Celltrion Ireland USA, Eli Lilly, Ireland, M.S.D. Ireland, Amgen Ireland, Amgen Europe, Abbvie Ireland, Proctor and Gamble Ireland and U.K., Novartis Ireland, UCB Ireland, UK and Europe. Current funding: Health Research Board, Ireland: \u20ac0.5M: SDAP 2021_001: The DXA MAP Project. J.M: Research funds: A. Menarini Diagnostics, GlucoSet, Roche Advisory board: Abbott Diabetes Care, Becton-Dickinson\/Embecta, Biomea, Eli Lilly, Dexcom, Insulet, Medtronic, Novo Nordisk, Pharmasens, Roche Diabetes Care, Sanofi, Tandem, Viatris Speaker: Abbott Diabetes Care, A. Menarini Diagnostics, Becton-Dickinson\/Embecta, Dexcom, Eli Lilly, MedTrust, Novo Nordisk, Roche Diabetes Care, Sanofi, Sinocare, Ypsomed Shareholder: decide Clinical Software GmbH, elyte Diagnostics. K.D: In the last 12 months, I have received honoraria, travel, or fees for speaking or advisory boards from: Abbott Diabetes, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Menarini, Novo Nordisk, Roche, Sanofi Diabetes. M.S Consultant and Ad Board: IBSA, ArgenX, Third Rock Ventures, Tourmaline, Immunovant, Lycia, Amgen, Viridian, Merck, RocheSpeaker\u2019s fee: IBSA, Amgen \u00a0Research Funding (to the Institution) for clinical trials: Roche, GSK , Viridian, Sling Therapeutics, Immunovant, Amgen, ArgenX, Acelyrin.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}